Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult

Stem Cells

Volumn 25, Issue 12, 2007, Pages 2976-2986

  Motoda, Lena ^a,b   Osato, Motomi ^a,c   Yamashita, Namiko ^a   Jacob, Bindya ^a   Chen, Lynnette Q ^a   Yanagida, Masatoshi ^a   Ida, Hiroshi ^a   Wee, Hee Jun ^a   Sun, Alfred X ^a   Taniuchi, Ichiro ^d   Littman, Dan ^e   Ito, Yoshiaki ^a,c  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d RIKEN Center for Integrative Medical Sciences   (Japan)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AML1; c Kit; FLT3; Runx; Senescence

Indexed keywords

TRANSCRIPTION FACTOR RUNX1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BMI 1 GENE; C57BL 6 MOUSE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROTECTION; CELL RENEWAL; CONTROLLED STUDY; GENE; GENE ACTIVATION; GENE INACTIVATION; HEMATOPOIETIC STEM CELL; LEUKEMIA; MOUSE; NONHUMAN; ONCOGENE N RAS; PROTEIN FUNCTION; RUNX1 GENE; SENESCENCE;

ANIMALS; APOPTOSIS; CELL SURVIVAL; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GENES, RAS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASTIC STEM CELLS;

EID: 37349112219     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2007-0061     Document Type: Article

References (46)

1. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005;5:311-321.
2. van Wijnen AJ, Stein GS, Gergen JP et al. Nomenclature for Runt-related (RUNX) proteins. Oncogene 2004;23:4209-4210.
3. Okuda T, van Deursen J, Hiebert SW et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996;84:321-330.
4. Wang Q, Stacy T, Binder M et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A 1996;93:3444-3449.
5. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer 2002;2:502-513.
6. Castilla LH, Wijmenga C, Wang Q et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell 1996;87:687-696.
7. Yergeau DA, Hetherington CJ, Wang Q et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 1997;15:303-306.
8. Osato M. Point mutations in the RUNX1/AML1 gene: Another actor in RUNX leukemia. Oncogene 2004;23:4284-4296.
9. Song WJ, Sullivan MG, Legare RD et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999;23:166-175.
10. Goemans BF, Zwaan CM, Miller M et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005;19:1536-1542.
11. Yamashita N, Osato M, Huang L et al. Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice. Br J Haematol 2005;131:495-507.
12. Christiansen DH, Andersen MK, Desta F et al. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2005;19:2232-2240.
13. Bedigian HG, Taylor BA, Meier H. Expression of murine leukemia viruses in the highly lymphomatous BXH-2 recombinant inbred mouse strain. J Virol 1981;39:632-640.
14. Okada H, Watanabe T, Niki M et al. AML1(-/-) embryos do not express certain hematopoiesis-related gene transcripts including those of the PU.1 gene. Oncogene 1998;17:2287-2293.
15. Taniuchi I, Osato M, Egawa T et al. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell 2002;111:621-633.
16. Kuhn R, Schwenk F, Aguet M et al. Inducible gene targeting in mice. Science 1995;269:1427-1429.
17. Buchberg AM, Bedigian HG, Jenkins NA et al. Evi-2, a common integration site involved in murine myeloid leukemogenesis. Mol Cell Biol 1990;10:4658-4666.
18. Largaespada DA, Shaughnessy JD Jr, Jenkins NA et al. Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels. J Virol 1995;69:5095-5102.
19. Ingram DA, Yang FC, Travers JB et al. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med 2000;191:181-188.
20. Al-Mulla F, Milner-White EJ, Going JJ et al. Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J Pathol 1999;187:433-438.
21. Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood 2006;108:2349-2357.
22. Okada S, Nakauchi H, Nagayoshi K et al. In vivo and in vitro stem cell function of c-kit- and Sca-1-positive murine hematopoietic cells. Blood 1992;80:3044-3050.
23. Ichikawa M, Asai T, Saito T et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 2004;10:299-304.
24. Growney JD, Shigematsu H, Li Z et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 2005;106:494-504.
25. Goodell MA, Brose K, Paradis G et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996;183:1797-1806.
26. Berardi AC, Wang A, Levine JD et al. Functional isolation and characterization of human hematopoietic stem cells. Science 1995;267:104-108.
27. Klampfer L, Zhang J, Zelenetz AO et al. The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci U S A 1996;93:14059-14064.
28. Yano T, Ito K, Fukamachi H et al. The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis. Mol Cell Biol 2006;26:4474-4488.
29. Opferman JT, Iwasaki H, Ong CC et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005;307:1101-1104.
30. Park IK, Qian D, Kiel M et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003;423:302-305.
31. Iwama A, Oguro H, Negishi M et al. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 2004;21:843-851.
32. Schmitt CA. Senescence, apoptosis and therapy - Cutting the lifelines of cancer. Nat Rev Cancer 2003;3:286-295.
33. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-737.
34. Braig M, Lee S, Loddenkemper C et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005;436:660-665.
35. Hibi S, Lohler J, Friel J et al. Induction of monocytic differentiation and tumorigenicity by v-Ha-ras in differentiation arrested hematopoietic cells. Blood 1993;81:1841-1848.
36. Passioura T, Dolnikov A, Shen S et al. N-ras-induced growth suppression of myeloid cells is mediated by IRF-1. Cancer Res 2005;65:797-804.
37. Shen S, Passioura T, Symonds G et al. N-ras oncogene-induced gene expression in human hematopoietic progenitor cells: Upregulation of p16INK4a and p21CIP1/WAF1 correlates with myeloid differentiation. Exp Hematol 2007;35:908 -919.
38. Campisi J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 2001;11:S27-31.
39. Yamaguchi-Iwai Y, Satake M, Murakami Y et al. Differentiation of F9 embryonal carcinoma cells induced by the c-jun and activated c-Ha-ras oncogenes. Proc Natl Acad Sci U S A 1990;87:8670-8674.
40. Ferbeyre G, de Stanchina E, Lin AW et al. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 2002;22:3497-3508.
41. Serrano M, Lin AW, McCurrach ME et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
42. Lutterbach B, Westendorf J, Linggi B et al. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem 2000;275:651-656.
43. Matsuda K, Shimada A, Yoshida N et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood 2007;109:5477-5480.
44. Yoshida N, Yagasaki H, Xu Y et al. Correlation of clinical features with mutation status in children with juvenile myelomonocytic leukemia. Blood 2006;108:760a.
45. Linggi B, Muller-Tidow C, van de Locht L et al. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 2002;8:743-750.
46. Shikami M, Miwa H, Nishii K et al. Low p53 expression of acute myelocytic leukemia cells with t(8;21) chromosome abnormality: Association with low p14(ARF) expression. Leuk Res 2006;30:379-383.